Puma Biotechnology Inc. (0PB)

Overview

Puma Biotechnology, Inc. is a biopharmaceutical company with a sharp focus on the development and commercialization of innovative products aimed at improving cancer care, both within the United States and globally. Since its establishment in 2010, the company has been dedicated to bringing forward novel therapies that cater to specific cancer care needs. With headquarters in Los Angeles, California, Puma Biotechnology has built a strong presence in the oncology space through its strategic license agreements for the development, manufacture, and commercialization of key compounds with leading pharmaceutical companies such as Pfizer Inc. and Takeda Pharmaceutical Company Limited. Moreover, the company extends its market reach through sub-license agreements with several international pharmaceutical companies, facilitating the global distribution of its oncology products.

Products and Services

• NERLYNX (neratinib, oral)

  This is an oral medication developed by Puma Biotechnology, designed specifically for the treatment of adult patients who are dealing with early-stage HER2-overexpressed/amplified breast cancer. In addition, NERLYNX, when combined with capecitabine, is indicated for patients suffering from advanced or metastatic HER2-positive breast cancer. This highlights the company's dedication to providing targeted therapies for patients with specific cancer types, offering them a chance for a better quality of life and improved treatment outcomes.

• Alisertib (small molecule inhibitor of aurora kinase A)

  Currently under development, alisertib represents Puma Biotechnology's commitment to expanding its oncology portfolio. This small molecule inhibitor targets aurora kinase A, a protein associated with cellular division and is implicated in various types of cancer. Puma Biotechnology is exploring alisertib's potential in treating hormone receptor-positive breast cancer, triple-negative breast cancer, small cell lung cancer, and head and neck cancer. This signifies the company's investment in broadening the scope of its research and development efforts to encompass a wider array of cancer types, aiming to fill therapy gaps and meet the diverse needs of cancer patients.